Fevaxyn Quatrifel, Injeksjonsvæske, suspensjon, til katt
Fevaxyn Quatrifel, Injeksjonsvæske, suspensjon, til katt
Not authorised
- Chlamydia felis, strain Cello, Inactivated
- Felid herpesvirus 1, Inactivated
- Feline calicivirus, strain 255, Inactivated
- Feline panleucopenia virus, strain CU4, Inactivated
Product identification
Medicine name:
Fevaxyn Quatrifel, Injeksjonsvæske, suspensjon, til katt
Active substance:
- Chlamydia felis, strain Cello, Inactivated
- Felid herpesvirus 1, Inactivated
- Feline calicivirus, strain 255, Inactivated
- Feline panleucopenia virus, strain CU4, Inactivated
Target species:
-
Cat
Route of administration:
-
Subcutaneous use
-
Intramuscular use
Product details
Active substance and strength:
-
Chlamydia felis, strain Cello, Inactivated1.69/relative potency1.00millilitre(s)
-
Felid herpesvirus 1, Inactivated1.39/relative potency1.00millilitre(s)
-
Feline calicivirus, strain 255, Inactivated1.26/relative potency1.00millilitre(s)
-
Feline panleucopenia virus, strain CU4, Inactivated8.50/relative potency1.00millilitre(s)
Pharmaceutical form:
-
Suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI06AL02
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Surrendered
Authorised in:
-
Norway
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Animal Health ApS
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- Norwegian Medical Products Agency
Authorisation number:
- 8127
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Norwegian (PDF)
Published on: 30/03/2022